Wait, so we’re doing PSA again? The ProtecT trial and the rise, fall, and resurrection of prostate cancer screening

Yesterday we talked about PSA, the molecule you hate to need, and certainly one of the most frustrating cancer screening methods in history. We reviewed how trials of population-level screening for asymptomatic patients demonstrated a small mortality benefit, but at the cost of significant overdiagnosis of prostate cancer. And yet the USPSTF is changing their […]